ArticleBMC infectious diseases2025
Adherence to isoniazid and rifapentine preventive therapy for better treatment outcomes among adults living with HIV in public health facilities in Addis Ababa: a multicenter study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tuberculosis Incidence and Predictors Among People Living With HIV After Isoniazid-Rifapentine (3HP) Preventive Therapy in Ethiopia: A Retrospective Cohort Study.Journal of tropical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a serious public health problem among people living with HIV (PLHIV), and preventive measure is therefore essential. To scale up TB prevention, Ethiopia has rolled out a preventive regimen consisting of isoniazid and rifapentine taken once weekly for three months (3HP). In spite of its paramount importance, limited evidence exists on adherence to this regimen among adults living with HIV in Addis Ababa. Therefore, this study assessed adherence to 3HP and factors influencing it among PLHIV receiving care in public health facilities.
methodsA facility-based cross-sectional study was conducted from July 20 to September 3, 2023, among 375 PLHIV receiving 3HP in selected public health facilities in Addis Ababa. Participants were enrolled using systematic sampling. Data were collected using interviewer-administered questionnaires and patient records. Multivariable logistic regression analysis was performed to identify factors associated with adherence. Adjusted odds ratios (AOR) with 95% confidence intervals (CI) were reported, and statistical significance was set at p < 0.05.
resultsOverall, adherence to 3HP therapy was 92.5% (95% CI: 89.42–94.78%). Non-substance use was positively associated with 3HP adherence (AOR = 2.74; 95% CI: 1.19–5.54). While, ART discontinuation (AOR = 0.14, 95% CI: 0.06–0.34), long waiting times (AOR = 0.22, 95% CI: 0.1–0.50), and reported 3HP-related side effects (AOR = 0.08; 95% CI: 0.01–0.42) were negatively associated with 3HP adherence.
conclusionAdherence to 3HP preventive therapy among adults living with HIV in Addis Ababa was relatively high. Strengthening counseling for substance users, supporting ART adherence, and improving service efficiency may further enhance adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.